Tuesday, December 1, 2020

admin

848 POSTS2 COMMENTS

Eisai and Wren Therapeutics Enter Into Research Collaboration Agreement for Drug Discovery for Synucleinopathies

November 30, 2020: Eisai and Wren Therapeutics announced that the companies have entered into an exclusive research collaboration agreement aiming to advance...

AstraZeneca agreed to sell rights to Crestor to be divested to Grünenthal in Europe

December 01, 2020: AstraZeneca has agreed to sell the rights to Crestor (rosuvastatin) and associated medicines in over 30 countries in Europe, except the...

AstraZeneca’sForxiga approved in Japan for chronic heart failure

November 30, 2020: AstraZeneca’s Forxiga (dapagliflozin) has been approved in Japan for the treatment of patients with chronic heart failure (HF) who are receiving...

Moderna Announces the EC Approval for Initial 80 Million Doses of mRNA Vaccine Against COVID-19

November 25, 2020: "Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines...

BMS Receives EC Approval for Opdivo for Esophageal Squamous Cell Carcinoma

Nov 25, 2020: Bristol Myers Squibb announced that the European Commission (EC) has approved Opdivo (nivolumab) for the treatment of adults with unresectable advanced, recurrent or...

Amgen To Transition Development And Commercial Rights to Cytokinetics

Nov. 23, 2020: Amgen announced the Company has provided notice to Cytokinetics of termination of its collaboration and its intention to transition the...

CRASH COURSE ON CLINICAL DATA MANAGEMENT

Specially designed Course for Freshers and entry Level Professionals on Clinical Data Management  is going to be held 29 Nov (Sunday) from...

AZ’s Imfinzi approved in the US for less-frequent, fixed-dose use

November 20, 2020: "AstraZeneca’s Imfinzi (durvalumab) has been approved in the US for an additional dosing option, a 1,500mg fixed dose every four weeks,...

Novartis secures exclusive rights for potential ARD syndrome cell therapy

November 19, 2020: "Novartis announced today that it entered into an exclusive worldwide license and collaboration agreement with Mesoblast to develop, commercialize and...

Sosei Heptares’ COVID-19 programme advances promising molecules

November 20, 2020: "Sosei Group Corporation announces a progress update for its R&D program focused on the design and development of novel...

ViiV Healthcare announces results of the PROgress study for improving HIV care

November 18, 2020: "ViiV Healthcare, with Pfizer Inc. and Shionogi Limited as shareholders announced positive initial findings from the PROgress study,...

Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate

November 18, 2020: "Pfizer and BioNTech announced that, after conducting the final efficacy analysis in their ongoing Phase 3 study, their mRNA-based...

TOP AUTHORS

848 POSTS2 COMMENTS

Most Read

Eisai and Wren Therapeutics Enter Into Research Collaboration Agreement for Drug Discovery for Synucleinopathies

November 30, 2020: Eisai and Wren Therapeutics announced that the companies have entered into an exclusive research collaboration agreement aiming to advance...

AstraZeneca agreed to sell rights to Crestor to be divested to Grünenthal in Europe

December 01, 2020: AstraZeneca has agreed to sell the rights to Crestor (rosuvastatin) and associated medicines in over 30 countries in Europe, except the...

AstraZeneca’sForxiga approved in Japan for chronic heart failure

November 30, 2020: AstraZeneca’s Forxiga (dapagliflozin) has been approved in Japan for the treatment of patients with chronic heart failure (HF) who are receiving...

Moderna Announces the EC Approval for Initial 80 Million Doses of mRNA Vaccine Against COVID-19

November 25, 2020: "Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines...